All In Biotech

Drug Trial Radar · NCT05305599

Different Doses of ZED1227 vs. Placebo in NAFLD

Double-blind, Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of ZED1227 Capsules With Placebo in the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) With Significant Fibrosis

Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Apr 19, 2022

Primary completion

Jun 7, 2023

Study completion Jul 5, 2023

Sponsor

Lead sponsor
Dr. Falk Pharma GmbHIndustry
Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with fibrosis.

Conditions

  • NAFLD
  • Liver Fibrosis

Interventions

  • ZED1227Drug

    ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change of PRO-C3 levelsTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz

    Mainz, Rhineland-Palatinate, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.